仿制药-话题@MedSci

#仿制药#

261篇内容 | 5549人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1261414, encodeId=a7ac1261414d2, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=纳米类似药何去何从——再议原研药与仿制药的差异, objectType=article, longId=139553, objectId=f7871395539c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7871395539c, replyNumber=0, likeNumber=90, createdTime=2018-06-01, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7871395539c, moduleTitle=纳米类似药何去何从——再议原研药与仿制药的差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f7871395539c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261413, encodeId=c74012614137d, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=欧盟通过Sandoz的Remicade生物仿制药Zessly, objectType=article, longId=139097, objectId=b7a513909e06, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7a513909e06, replyNumber=0, likeNumber=66, createdTime=2018-05-26, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7a513909e06, moduleTitle=欧盟通过Sandoz的Remicade生物仿制药Zessly, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7a513909e06)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261412, encodeId=0d681261412a2, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA批准辉瑞的生物仿制药Retacrit, objectType=article, longId=138358, objectId=39b313835837, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39b313835837, replyNumber=0, likeNumber=69, createdTime=2018-05-18, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39b313835837, moduleTitle=FDA批准辉瑞的生物仿制药Retacrit, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39b313835837)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261411, encodeId=dade1261411b9, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=取消药品加成后，为何便宜的国产仿制药仍不受青睐？, objectType=article, longId=137865, objectId=ffe813e865a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffe813e865a9, replyNumber=0, likeNumber=57, createdTime=2018-05-12, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffe813e865a9, moduleTitle=取消药品加成后，为何便宜的国产仿制药仍不受青睐？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffe813e865a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261410, encodeId=5b6b126141003, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=中国仿制药市场大盘点, objectType=article, longId=137773, objectId=a56d13e7738a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a56d13e7738a, replyNumber=0, likeNumber=62, createdTime=2018-05-12, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a56d13e7738a, moduleTitle=中国仿制药市场大盘点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a56d13e7738a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261409, encodeId=dce7126140965, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=高质量仿制药亟待政策护航, objectType=article, longId=137765, objectId=b2f813e76555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2f813e76555, replyNumber=0, likeNumber=50, createdTime=2018-05-12, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2f813e76555, moduleTitle=高质量仿制药亟待政策护航, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2f813e76555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261408, encodeId=f83a1261408d2, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药再提速多地招采出新政支持一致性评价产品, objectType=article, longId=137701, objectId=d2f613e70171, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2f613e70171, replyNumber=0, likeNumber=59, createdTime=2018-05-11, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2f613e70171, moduleTitle=仿制药再提速多地招采出新政支持一致性评价产品, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2f613e70171)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261407, encodeId=9101126140e42, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=央视报道，国产仿制药的不公正待遇，该结束了, objectType=article, longId=137623, objectId=c47d13e623d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c47d13e623d2, replyNumber=0, likeNumber=50, createdTime=2018-05-11, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c47d13e623d2, moduleTitle=央视报道，国产仿制药的不公正待遇，该结束了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c47d13e623d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261406, encodeId=e7df126140648, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=诺华生物仿制药Rituxan在美国推迟使用, objectType=article, longId=137365, objectId=0aa213e3653f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0aa213e3653f, replyNumber=0, likeNumber=78, createdTime=2018-05-08, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0aa213e3653f, moduleTitle=诺华生物仿制药Rituxan在美国推迟使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0aa213e3653f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261405, encodeId=e7e7126140555, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=欧洲推出Herceptin生物仿制药Herzuma, objectType=article, longId=137306, objectId=3a5a13e306c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a5a13e306c6, replyNumber=0, likeNumber=61, createdTime=2018-05-06, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a5a13e306c6, moduleTitle=欧洲推出Herceptin生物仿制药Herzuma, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a5a13e306c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261404, encodeId=6a0f1261404a6, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=BMJ：授权仿制药PK仿制药哪种更容易导致患者换回品牌药？, objectType=article, longId=137217, objectId=b42b13e217df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b42b13e217df, replyNumber=0, likeNumber=55, createdTime=2018-05-06, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b42b13e217df, moduleTitle=BMJ：授权仿制药PK仿制药哪种更容易导致患者换回品牌药？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b42b13e217df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261403, encodeId=8c8f12614031c, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=比较SB3（曲妥珠单抗生物仿制药）和曲妥珠单抗治疗HER2阳性早期乳腺癌的III期研究：最终安全性，免疫原性和存活, objectType=article, longId=136871, objectId=94111368e1b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94111368e1b3, replyNumber=0, likeNumber=58, createdTime=2018-05-01, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94111368e1b3, moduleTitle=比较SB3（曲妥珠单抗生物仿制药）和曲妥珠单抗治疗HER2阳性早期乳腺癌的III期研究：最终安全性，免疫原性和存活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94111368e1b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261402, encodeId=2855126140250, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药发展迎来全面“大提速”, objectType=article, longId=136562, objectId=209713656254, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=209713656254, replyNumber=0, likeNumber=0, createdTime=2018-04-28, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=209713656254, moduleTitle=仿制药发展迎来全面“大提速”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=209713656254)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261401, encodeId=05eb126140168, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药学术营销之道, objectType=article, longId=136418, objectId=dbda1364182f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbda1364182f, replyNumber=0, likeNumber=80, createdTime=2018-04-27, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbda1364182f, moduleTitle=仿制药学术营销之道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbda1364182f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261400, encodeId=c5f812614007b, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药新政，千家药企将消失！, objectType=article, longId=135529, objectId=ef2e1355293e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef2e1355293e, replyNumber=0, likeNumber=51, createdTime=2018-04-18, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef2e1355293e, moduleTitle=仿制药新政，千家药企将消失！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef2e1355293e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261399, encodeId=27ca126139945, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=彭博社：利润空间收窄仿制药或将消失, objectType=article, longId=135492, objectId=25be13549216, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25be13549216, replyNumber=0, likeNumber=59, createdTime=2018-04-18, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25be13549216, moduleTitle=彭博社：利润空间收窄仿制药或将消失, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25be13549216)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261398, encodeId=1f26126139898, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=新华社：仿制药新政让患者不再望“药”兴叹, objectType=article, longId=135087, objectId=0bdb13508e43, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bdb13508e43, replyNumber=0, likeNumber=78, createdTime=2018-04-14, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bdb13508e43, moduleTitle=新华社：仿制药新政让患者不再望“药”兴叹, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bdb13508e43)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261397, encodeId=52f5126139e53, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=印度仿制药的成功带给中国的思考, objectType=article, longId=135038, objectId=629e135038bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=629e135038bd, replyNumber=0, likeNumber=60, createdTime=2018-04-13, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=629e135038bd, moduleTitle=印度仿制药的成功带给中国的思考, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=629e135038bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261396, encodeId=8c8c126139687, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=质量上得去市场推得开：聚焦仿制药新政三大看点, objectType=article, longId=134684, objectId=6df8134684f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6df8134684f6, replyNumber=0, likeNumber=74, createdTime=2018-04-11, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6df8134684f6, moduleTitle=质量上得去市场推得开：聚焦仿制药新政三大看点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6df8134684f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261395, encodeId=4889126139564, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=刘谦：政府搞仿制药替代只是补了欠账，不是让你发财, objectType=article, longId=134635, objectId=fecb1346350f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fecb1346350f, replyNumber=0, likeNumber=0, createdTime=2018-04-11, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fecb1346350f, moduleTitle=刘谦：政府搞仿制药替代只是补了欠账，不是让你发财, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fecb1346350f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

仿制药

2020-05-29

drwjr (审核中...)

前往app查看评论内容

#仿制药#

纳米类似药何去何从——再议原研药与仿制药的差异

2018-06-01

drwjr (审核中...)

前往app查看评论内容

#仿制药#

欧盟通过Sandoz的Remicade生物仿制药Zessly

2018-05-26

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA批准辉瑞的生物仿制药Retacrit

2018-05-18

drwjr (审核中...)

前往app查看评论内容

#仿制药#

取消药品加成后，为何便宜的国产仿制药仍不受青睐？

2018-05-12

drwjr (审核中...)

前往app查看评论内容

#仿制药#

中国仿制药市场大盘点

2018-05-12

drwjr (审核中...)

前往app查看评论内容

#仿制药#

高质量仿制药亟待政策护航

2018-05-12

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药再提速多地招采出新政支持一致性评价产品

2018-05-11

drwjr (审核中...)

前往app查看评论内容

#仿制药#

央视报道，国产仿制药的不公正待遇，该结束了

2018-05-11

drwjr (审核中...)

前往app查看评论内容

#仿制药#

诺华生物仿制药Rituxan在美国推迟使用

2018-05-08

drwjr (审核中...)

前往app查看评论内容

#仿制药#

欧洲推出Herceptin生物仿制药Herzuma

2018-05-06

drwjr (审核中...)

前往app查看评论内容

#仿制药#

BMJ：授权仿制药PK仿制药哪种更容易导致患者换回品牌药？

2018-05-06

drwjr (审核中...)

前往app查看评论内容

#仿制药#

比较SB3（曲妥珠单抗生物仿制药）和曲妥珠单抗治疗HER2阳性早期乳腺癌的III期研究：最终安全性，免疫原性和存活

2018-05-01

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药发展迎来全面“大提速”

2018-04-28

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药学术营销之道

2018-04-27

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药新政，千家药企将消失！

2018-04-18

drwjr (审核中...)

前往app查看评论内容

#仿制药#

彭博社：利润空间收窄仿制药或将消失

2018-04-18

drwjr (审核中...)

前往app查看评论内容

#仿制药#

新华社：仿制药新政让患者不再望“药”兴叹

2018-04-14

drwjr (审核中...)

前往app查看评论内容

#仿制药#

印度仿制药的成功带给中国的思考

2018-04-13

智者为医08 (审核中...)

前往app查看评论内容

#仿制药#

质量上得去市场推得开：聚焦仿制药新政三大看点

2018-04-11

drwjr (审核中...)

前往app查看评论内容

#仿制药#

刘谦：政府搞仿制药替代只是补了欠账，不是让你发财

2018-04-11

科室
- - 订阅+
  - 更多科室
工具
服务